Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 8Classical hematology 3Thoracic 2Sarcoma 2Plasma cell 2Myeloid 2Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Desmoplastic Small Round Cell Tumor 1

Interventions

Cyclophosphamide 55Specimen Handling 50Magnetic Resonance Spectroscopy 49Doxorubicin 44pembrolizumab 43Radiotherapy 42Temozolomide 38Biopsy 34Radiation 29Nivolumab 28fludarabine 23Vincristine 22Irinotecan 21Gemcitabine 21X-Rays 20Ifosfamide 20Surgical Procedures, Operative 19atezolizumab 17cabozantinib 15Ipilimumab 15olaparib 13Sunitinib 13Paclitaxel 13Etoposide 13Blood Specimen Collection 13regorafenib 12fludarabine phosphate 12Phantoms, Imaging 12Imatinib Mesylate 12liposomal doxorubicin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Sarcoma × 1 year × Clear all
NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT06709495 2026-02-19

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
63 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡